Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.

@article{Ramanathan2007PharmacokineticsOC,
  title={Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.},
  author={Srinivasan Valady Ramanathan and Gong Xin Shen and John Hinkle and Jeffrey V Enejosa and Brian P. Kearney},
  journal={Journal of acquired immune deficiency syndromes},
  year={2007},
  volume={46 2},
  pages={160-6}
}
OBJECTIVE To evaluate the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (EVG/r) and the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine (ZDV), didanosine (ddI), stavudine (d4T), or abacavir (ABC) upon coadministration. METHODS In 3 studies, healthy subjects were administered a single dose of ddI, d4T, or ABC, or multiple doses of ZDV, followed by multiple doses of EVG/r alone and together with an NRTI; pharmacokinetics (PK) of EVG… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Drug interactions with new and investigational antiretrovirals.

Clinical pharmacokinetics • 2009
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…